Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye injections could clear Diabetes-Related bleeding and save sight

NCT ID NCT07690800

Disease control Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether injections of ranibizumab, a drug that blocks abnormal blood vessel growth, can help clear bleeding inside the eye in people with diabetes. The bleeding, called diabetic vitreous hemorrhage, can blur or block vision. Participants receive the injection and are followed for 3 to 6 months to see if their vision improves, the bleeding clears, and whether they can avoid more invasive surgery. The trial includes adults aged 20 to 70 with diabetes-related eye bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ranibizumab (Lucentis)
What this could lead to
If it works, this could offer a less invasive way to clear bleeding in the eye from diabetes, potentially saving vision and avoiding surgery.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Risks include eye infection, inflammation, or the bleeding not clearing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Apr 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 20 to 70 years. * Type 1 or Type 2 diabetes mellitus. * Diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy. * Treatment-naïve diabetic vitreous hemorrhage or recurrent/residual vitreous hemorrhage following previous panretinal photocoagulation. * Phakic or pseudophakic eyes. * Able and willing to provide written informed consent. Exclusion Criteria: * Significant tractional retinal detachment or retinal traction requiring immediate surgery. * Previous ocular surgery other than cataract surgery. * Previous intravitreal pharmacologic treatment within the preceding 6 months. * Any type of glaucoma. * Active ocular infection or significant ocular surface disease. * No light perception vision. * Known hypersensitivity to ranibizumab or any component of the study medication. * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic vitreous hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

proliferative diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic vitreous hemorrhage Intravitreal injections Ranibizumab

Contacts and locations

Locations

  • Benha University

    Banhā, Benha, 13111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.